Olympic Sex Testing Controversy: Italian Doctors Warn of Science Gone Backwards

The International Olympic Committee (IOC) has announced plans to reintroduce genetic sex testing for Olympic athletes ahead of the 2028 Los Angeles Olympics, a decision that has triggered sharp criticism from Italian sports medicine experts who argue the measure is scientifically incomplete and risks creating an unjust system for female competitors.

The Core Scientific Problem

Professor Luigi Di Luigi, a leading endocrinologist at Rome's Università del Foro Italico, addressed the controversy at the ongoing national congress of sports physicians in the Italian capital. His central concern: the IOC's approach focuses exclusively on the SRY gene (Sex-determining Region Y), a genetic marker on the Y chromosome responsible for triggering male sexual development—but this narrow focus captures only a fraction of the medical conditions that affect competitive fairness.

"The IOC tests do not cover all possible clinical pictures related to hyperandrogenism and disorders of sexual differentiation," Di Luigi explained. "They cover only a part—and not even the most numerous one."

The test is designed to identify athletes with certain hormonal or developmental conditions, but Di Luigi warns it creates a system riddled with gaps.

What the Test Misses

The IOC's protocol screens for the SRY gene to flag athletes who may have differences of sexual development (DSD) or elevated testosterone levels. However, Di Luigi points out that many female athletes with XX chromosomes experience hormonal or developmental conditions that produce testosterone levels and physical advantages comparable to those the IOC aims to catch—yet these athletes would pass the SRY test because they lack the Y chromosome marker.

"You lose in the testing all those pathologies where athletes have female chromosomes but in a disease context that places them in the same conditions as athletes for whom hyperandrogenism is detected," Di Luigi said. "To be just, fair, and honest, either you address all similar problems not detected by the SRY antigen, or you shouldn't do anything at all."

The practical result: some athletes with competitive advantages go undetected while others face eligibility questions based on a genetic marker that doesn't capture the full medical picture.

Confusing Different Issues

Di Luigi also emphasizes that the IOC's approach conflates distinct medical and ethical matters. The policy treats transgender participation the same way it treats disorders of sexual differentiation—but these are fundamentally different questions requiring different frameworks.

"The issue of transgender athletes must be separated from that of hyperandrogenism and disorders of sexual differentiation," he explained. "The IOC measure treats them the same way and at the same level, but they are completely different questions. The first is essentially ideological, cultural, ethical. The situation that can be detected with the SRY antigen is only part of the 'critical' cases."

On the political context surrounding the debate, Di Luigi acknowledged that figures including U.S. President Donald Trump have raised gender eligibility as a cultural issue. "Scientifically, there is a serious basis on this topic," he noted. However, he stressed that the medical community must focus on clinical evidence rather than ideological positioning, particularly when addressing intersex or DSD conditions, which are health issues first and competitive fairness questions second.

Unanswered Questions for Athletes

The IOC has not clarified what happens after a positive SRY test, nor has it established clear pathways for athletes to understand their status or pursue medical solutions.

"There are individuals who test SRY-positive yet are completely female—this can happen with certain diseases," Di Luigi noted. "The IOC tells you, 'I catch you positive first and then I study you,' but the problem comes before, not after."

He pointed to a hypothetical example involving Imane Khelif, the Algerian boxer whose participation in recent international events sparked global debate: "If she had been treated as a child, would she have been allowed to compete even if she tested positive?" The question underscores a critical gap: athletes and their families deserve to know whether early medical intervention could preserve eligibility, and what standards will govern individual assessments.

What This Means for Italy

Italy maintains a well-established tradition in sports medicine, with rigorous pre-competition health screenings mandated for all athletes at professional and amateur levels. Italian specialists now face questions about how their own federations will respond to the IOC decision.

The Rome congress where Di Luigi spoke serves as a key forum for shaping Italy's recommendations to international bodies. Italian experts are calling for the IOC to convene a multidisciplinary panel including endocrinologists, geneticists, ethicists, and athlete representatives to develop a more comprehensive framework before the Los Angeles Games.

For Italian athletes, coaches, and federations, the uncertainty about how the IOC will implement this policy—and whether Italian guidelines will align with international standards—creates immediate practical concerns. Italian sports bodies will likely need to clarify their own policies to provide athletes with clear guidance.

The debate also carries broader implications for Italy's legal framework. While Italian law does not currently address transgender athlete participation at the elite level, an increasingly polarized international debate may prompt domestic sports federations to establish clearer guidelines on gender eligibility in competition.